The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China.

Qingxiao Chen,Xiaoyan Han,Gaofeng Zheng,Yang Yang,Yi Li,Enfan Zhang,Li Yang,Mengmeng Dong,Donghua He,Jingsong He,Zhen Cai

Frontiers in oncology（2022）

Cited 1|Views11

No score

Abstract

+1q is associated with a higher tumor burden and correlated with the occurrence of del(13q) and IgH rearrangement at diagnosis. In the era of novel agents, +1q still significantly affects PFS and OS.

Translated text

Key words

1q gain,bortezomib,chinese population,myeloma,single center

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined